#United States #New York #Pomerantz Law #SEC Investigations #argenx SE

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Argenx SE

Pomerantz LLP, a prominent law firm known for its work in securities and class action litigation, has initiated an investigation concerning Argenx SE, a biotechnology company listed on NASDAQ under the ticker ARGX. This inquiry comes in response to alarms raised about potential securities fraud and unlawful business practices connected to the company. The law firm is reaching out to investors who may have been affected by these policies and practices, inviting them to share their experiences and participate in any forthcoming legal actions.

The backdrop of this investigation centers on a significant announcement issued on June 30, 2025, by the U.S. Food and Drug Administration (FDA). In this alert, the FDA indicated that there might be serious risks associated with Argenx's therapeutic product, Vyvgart Hytrulo. Specifically, the FDA warned about a potential link between the drug and severe exacerbations of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a serious neurological condition. The alert stated that the FDA is actively evaluating whether regulatory actions are necessary due to the adverse events reported to the FDA’s Adverse Event Reporting System.

In the wake of the FDA's announcement, Argenx's American Depositary Shares (ADS) experienced a downward shift, declining by $8.92, or approximately 1.59%, closing at $551.22 on the same day. This reaction signifies the market's immediate response to safety concerns that could impact the company's reputation and financial standing.

Pomerantz is well-recognized for its advocacy on behalf of investors, pioneering strategies in the realm of securities class actions. Founded by the late Abraham L. Pomerantz, a figure known as the 'dean of the class action bar,' the firm has over 85 years of experience in tackling issues of securities fraud, breaches of fiduciary duties, and misconduct by corporations. The firm has secured multi-million-dollar settlements for affected investors in various cases, continuing its legacy of protecting shareholder rights.

Danielle Peyton, an attorney with Pomerantz, is leading the investigation and encourages investors to reach out for more information. She can be contacted directly at [email protected] or via phone at 646-581-9980, ext. 7980. Those interested in joining the class action suit against Argenx are advised to take action promptly, as legal proceedings can have tight timelines.

The fallout from the FDA alert exemplifies how quickly investor sentiment can shift, particularly in the volatile field of biotechnology, where product safety is paramount. As the investigation unfolds, many stakeholders are keenly observing how the situation evolves. Investors are urged to stay informed and consider participating in the legal processes available to them.

In conclusion, Pomerantz LLP remains at the forefront of defending the rights of aggrieved investors in situations like the one involving Argenx. With ongoing investigations into the company’s practices, it is crucial for shareholders to be vigilant and proactive. More details can be found on Pomerantz's official website, which outlines the firm's ethos and history in fighting for justice in the arena of corporate misconduct.